{"id":"NCT04605991","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)","officialTitle":"A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-11-04","primaryCompletion":"2022-02-04","completion":"2022-02-04","firstPosted":"2020-10-28","resultsPosted":"2023-03-03","lastUpdate":"2023-03-03"},"enrollment":187,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"LY900014","otherNames":[]},{"type":"DRUG","name":"Insulin Glargine","otherNames":[]}],"arms":[{"label":"LY900014","type":"EXPERIMENTAL"}],"summary":"This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine. Participants will use continuous glucose monitoring (CGM) (Freestyle Libre 14-day system) during the study.","primaryOutcome":{"measure":"Change From Baseline in Percentage of Time With Continuous Glucose Monitoring (CGM) Sensor Glucose Values Between 70-180 Milligrams/Deciliter (mg/dL) (3.9-10.0 Millimoles/Liter [mmol/L]) (Both Inclusive) During Daytime Period at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"LY900014","deltaMin":3.8,"sd":1.38}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":32,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["37029268"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/1o3M94i5GGiiJPY7Q2RZBo"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":176},"commonTop":[]}}